TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A definitive diagnosis of Type 1 Primary Hyperoxaluria (PHI) as confirmed by hepatic angiotensinogen (AGT) deficiency, biochemical criteria (marked hyperoxaluria and hyperglycolic aciduria) or mutation analysis (having a known PHI mutation)~2. Alanine-glyoxylate aminotransferase (AGXT) genotype known~3. Hyperoxaluria not fully corrected by 3 months of continuous Vitamin B6 (VB6) at doses of 8 mg/kg/d or more~4. Males or females, 6-70 years of age, inclusive~5. Preserved renal function, as defined by measured glomerular filtration rate (GFR) \> 30 ml/min/1.73 m\^2~6. Sexually active female patients of childbearing potential must practice adequate contraception during the treatment period and for 6 months after discontinuation of therapy. A pregnancy test obtained at entry prior to the initiation of treatment must be negative. Female patients must not be breast-feeding. Sexually active male patients must practice acceptable methods of contraception during the treatment period and for 6 months after discontinuation of therapy.~7. Written informed consent for participation in this study.~Exclusion Criteria:~1. Patients who are fully VB6 responsive (i.e., G170R homozygotes).~2. Prior recipients of liver transplantation performed for correction of AGT deficiency.~3. Pregnancy or breastfeeding~4. Unwillingness of patient and/or partner to use contraception during treatment.~5. Malignant disease (other than non-melanoma skin cancer) in the previous two years.~6. Markedly reduced renal function (Stage IV Chronic Kidney Disease or measured or estimated GFR \< 30 ml/min/1.73 m\^2)~7. Allergy to betaine or related compounds~8. History of papilledema or increased intracranial pressure.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Betaine (Type: EXPERIMENTAL): Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anakinra in Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent provided by the patient;~* age above 18 years;~* diagnosis of hidradenitis suppurativa; and~* disease of Hurley II or III severity stage~Exclusion Criteria:~* history of systemic lupus erythematosus, of rheumatoid arthritis of of seronegative inflammatory arthritis;~* any prior administration of any type of anti-TNF therapy over the last six months;~* administration of any live (attenuated) vaccine over the last 4 weeks;~* history of recurrent vein thrombosis or embolism compatible with anti-cardiolipin syndrome;~* any present or smoldering infection;~* hepatic dysfunction defined as any value of transaminases, of γ-glutamyl transpeptidase or of bilirubin\> 2 x upper normal limit;~* history of haematological or solid tumor malignancy, arterial hypertension, liver cirrhosis, HIV infection, and hepatitis virus B or C infection~* history of episodes mimicking demyelinating disorders or a definite diagnosis of multiple sclerosis~* any creatinine value above 1.5 mg/dl~* intake of corticosteroids defined as daily intake of prednisone or equivalent more than 1mg/kg for the last three weeks;~* neutropenia defined as \<1000 neutrophils/mm3; and~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Water for injection (Type: PLACEBO_COMPARATOR): Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
- Anakinra (Type: EXPERIMENTAL): Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes with Hemoglobin A1c equal to or less than 9.5% (equal to or less than 81 mmol/mol)~* Anti-hyperglycemic drug naive or treated with up to 2 oral hyperglycemic drugs with or without a glucagon-like peptide-1analog or basal insulin, or basal insulin alone~* On stable antihyperglycemic regimen for at least 3 months~* Age equal to or greater than 50 years with established clinical vascular disease, or age equal to or greater than 55 years and subclinical vascular disease or age equal to or greater than 60 years and at least 2 or more cardiovascular risk factors~Exclusion Criteria:~* Uncontrolled diabetes requiring immediate therapy~* History of severe hypoglycemia in past year~* Acute coronary or cerebrovascular event within past 2 months~* Planned or anticipated revascularization procedure~* History of pancreatitis, hepatic insufficiency , chronic renal failure or of C-cell thyroid disorder~* Pregnancy or planned pregnancy during the trial period~* Completed or withdrawn from any study investigating dulaglutide

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg Dulaglutide (Type: EXPERIMENTAL): Administered once weekly, subcutaneously
- Placebo (Type: PLACEBO_COMPARATOR): Administered once weekly, subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/dental examination.~* A minimum of 20 permanent gradable teeth~* Moderate gingivitis present at the screening visit in the opinion of the investigator~* A total of 20 bleeding sites or greater at baseline visit~* Positive response to bleeding on brushing present at the screening visit~Exclusion Criteria:~* Pregnant or breast feeding women~* Tobacco chewers~* Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participants or undermines the data validity.~* Recent history (within the last year) of alcohol or other substance abuse~* Participants requiring prophylactic antibiotic treatment prior to dental therapy~* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients~* Have current active caries or any medical conditions which may directly influence gingival bleeding~* Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations~* Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index~* Participation in another clinical study or receipt of an investigational drug or oral care product within 30 days of the screening visit~* An employee of the sponsor or the study site or members or their immediate family.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sodium bicarbonate plus sodium fluoride (Type: EXPERIMENTAL): Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
- Sodium fluoride (Type: ACTIVE_COMPARATOR): Toothpaste containing 1100 ppm fluoride as sodium fluoride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet intrauterine adhesions diagnostic criteria of ESGE.~2. Patients with clear consciousness, can correct understanding related content of the questionnaire.~Exclusion Criteria:~1. Have a history of mental illness.~2. Receiving psychological treatment currently.~3. Have acute mental disorders.~4. Experienced special stress life events within six months.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 46 Years
- Healthy Volunteers: t

Study Arms:
- MBSR Group (Type: EXPERIMENTAL): The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
- wait-list control group (Type: NO_INTERVENTION): The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of advanced/metastatic lung cancer~Exclusion Criteria:~* Previous treatment with chemotherapy~* Uncontrolled diabetes~* History/active cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 2 (Arms A & B) (Type: EXPERIMENTAL): CP-751,871 + paclitaxel + carboplatin
- Phase 1b (Type: EXPERIMENTAL): 1. Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~2. Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clarithromycin is an Adjunct to Scaling and Root Planing

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age ranged between 30- 50 years with chronic periodontitis~* Patients with Probing Depth (PD)- \>5mm, Clinical Attachment Level( CAL)- \>3mm~* Systemically healthy individuals~Exclusion Criteria:~* Patients below the age of 30 years~* Patients who have undergone periodontal therapy 3 months prior to study~* Active /passive smokers~* Any antibiotic use 3 months prior to study~* Pregnant women and lactating mothers~* Un co- operative/ retarded patients~* Drug allergy/ other allergies~* Any systemic diseases

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- test group (Type: EXPERIMENTAL): Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
- control (Type: NO_INTERVENTION): scaling and root planing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women over 18 years of age with serologically proven, primary CMV infection during the first trimester of pregnancy or periconceptionally~Exclusion Criteria:~* Patients with preexisting liver disease, renal dysfunction, bone marrow suppression or sensitivity to Acyclovir will be excluded from the study - as will patients receiving any antiviral therapy prior to the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Valacyclovir (Type: ACTIVE_COMPARATOR): Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female ≥35 years of age at the screening visit~2. Clinical diagnosis of chronic moderate to severe LBP (nonradiculopathic)for ≥3 months~3. History of regular analgesic medication~4. History of inadequate pain relief or intolerance to analgesics used for chronic LBP~5. Willing to discontinue current pain medication~Key Exclusion Criteria:~1. History of lumbosacral radiculopathy within the past 2 years~2. Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions~3. Recent use of longer acting pain medications~4. Evidence of destructive arthropathy~5. Other medical conditions that may interfere with participation or accurate assessments during the trial

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fasinumab 6 mg SC Q4W and Placebo IV Q8W (Type: EXPERIMENTAL): Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
- Fasinumab 9 mg SC Q4W and Placebo IV Q8W (Type: EXPERIMENTAL): Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
- Fasinumab 9 mg IV Q8W and Placebo SC Q4W (Type: EXPERIMENTAL): Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
- Placebo SC Q4W and Placebo IV Q8W (Type: EXPERIMENTAL): Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis C (CHC), genotype 1, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) according to standard of care and in line with the current local label~* If RBV was co-administered with the ABBVIE REGIMEN, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)~* Participants had to voluntarily sign and date an informed consent form prior to inclusion into the study~* Participants must not have participated or intended to participate in a concurrent interventional therapeutic trial~Exclusion Criteria:~- None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with HCV genotype 1 (Type: None): Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus with HbA1c \> 7.0%~* Body mass index \> 27 and \< 43 kg/m2~* Candidate for general anesthesia~Exclusion Criteria:~* Prior bariatric surgery of any kind~* Cardiovascular conditions including significant coronary artery disease, peripheral vascular disease, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension~* Kidney disease or chronic renal insufficiency with a creatinine level \> 1.8 mg/dl~* Known history of chronic liver disease (except for NAFLD/NASH)~* Gastrointestinal disorders, malabsorptive disorders, or inflammatory bowel disease~* Psychiatric disorders including dementia, active psychosis, severe depression requiring \> 2 medications, history of suicide attempts, alcohol or drug abuse within the previous 12 months~* Severe pulmonary disease defined as FEV1 \< 50% of predicted value~* Pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Medical therapy (Type: NO_INTERVENTION): Intensive medical therapy for diabetes
- Gastric Bypass (Type: ACTIVE_COMPARATOR): Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
- Sleeve Gastrectomy (Type: ACTIVE_COMPARATOR): Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete